Dianthus price target raised to $125 from $65 at LifeSci Capital

LifeSci Capital raised the firm’s price target on Dianthus (DNTH) to $125 from $65 and keeps an Outperform rating on the shares. Dianthus reported an earlier-than-expected “Go” decision in its Phase III CAPTIVATE trial for Chronic Inflammatory Demyelinating Polyneuropathy after reaching 20 confirmed responders before all planned patients completed Part A, suggesting stronger efficacy than anticipated, the analyst tells investors in a research note. The update supports dropping the lower dose in Part B, indicates potentially higher response rates than comparable studies, and continues to show a favorable safety profile with no serious treatment-related issues observed, the firm says.